CureVac SE

General information
CureVac SE
Friedrich-Miescher-Str. 15
72076 Tübingen, Baden-Württemberg
Germany

Contact person: Sarah Fakih, Vice President, Corporate Communications & Investo
Company main phone: +49 (7071) 98830
Website:  https://www.curevac.com
Year founded:2000
Source of foundation:Spin-off from university
Name of foundation source:University of Tuebingen
No. of employees: Worldwide:  904
Corporate description / mission:
CureVac SE is is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with expertise in developing, optimizing, and manufacturing this versatile biological molecule for medical purposes. The company has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases.
State of ownership: Private / independent
Headquarters: Yes
IPO (year): 2020
Categorization
Sector:
  • Biotechnology - Therapeutics and Diagnostics
Subsector:
  • Anti-infectives
  • Antibodies
  • Drug delivery
  • Immunotherapy
  • Nucleic acid drugs
  • Vaccines
Primary therapeutic areas:
  • Digestive system / gastroenterology
  • Diseases of the eye / ophthalmology
  • Infectious and parasitic diseases / infectiology / parasitology
  • Neoplasms / cancer / oncology
  • Respiratory / pulmonology
Business model:
  • R&D
Customer segments:
  • Large biotech & big pharma
  • Small biotech
Summary Products / Services / Technologies
Number of Biotech Products
Pre-clinical:11
Phase I:6
Phase II:4
Phase III:1
Technology used:
RNActive®
RNArt®
RNAntibody®
RNAdjuvant®
Financing details
Fiscal year (end of) 2022
Revenues:USD 67.42M
R&D expenses:USD 62.55M
No. of shares:223'883'008
Market cap. / valuation:USD 2'035.10M
Collaborations & Clients
Partnering strategy / collaborations:
Bill & Melinda Gates Foundation
Coalition for Epidemic Preparedness Innovations (CEPI)
CRISPR Therapeutics, etc.
© 2023 Biotechgate by Venture Valuation
X